Nikhil Patkar
@nvpatkar
Professor HemePath @TataMemorial
Leukemia Researcher, Genomics, Bioinformatics, Method Development, MRD, cfDNA, AI/ML Noob
đDad who tweets about đ science
ID: 77950640
https://nvpatkar.wixsite.com/research-group 28-09-2009 07:15:36
4,4K Tweet
2,2K Followers
675 Following
When it comes to TET2 mutations in CMML, more are better! Multiple TET2 mt offset the negative impacts of ASXL1 and RAS mutations in myelodysplastic and myeloproliferative CMML, respectively. Mrinal Patnaik nature.com/articles/s4137âŠ
Clonal haematopoiesis to clonal cytopenias: unravelling disease evolut... sciencedirect.com/science/articl⊠The Lancet Haematology Kristina Kirschner Yael Kusne Catherine Cargo #CH #CCUS #Agerelated #Contextrelevant Mayo Clinic Comprehensive Cancer Center Mayo Clinic
Just published in CancerMedicine 15 years of PBSC mobilization experience in Myeloma Even in the CAR-T era, collecting sufficient PBSCs is crucial. - GCSF+plerixafor comparable to chemo mobilization - If prior RT (to hematopoietic sites - spine, pelvis), chemo-mobn is better
Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. Saurabh Zanwar Shaji Kumar Leukemia Journal Link: nature.com/articles/s4137âŠ